Ziltivekimab 对 3-5 期 CKD 患者血红蛋白决定因素的影响:RESCUE 随机试验分析
RESCUE 试验探索性分析纳入 264 例 3-5 期 CKD 且 hs-CRP≥2 mg/L 的成人,随机接受安慰剂或 ziltivekimab 7.5/15/30 mg 皮下注射每 4 周一次。第 12 周时各剂量组血红蛋白较安慰剂显著升高,血清铁、总铁结合力和转铁蛋白饱和度亦显著增加,无重大安全信号。
要点
- Ziltivekimab 可显著升高 3-5 期 CKD 伴系统炎症患者的血红蛋白。
- Ziltivekimab 同时改善血清铁、总铁结合力和转铁蛋白饱和度。
- 各剂量组持续血小板减少、中性粒细胞减少及贫血事件少见且组间相似。
核心结论
- 抗炎治疗 ziltivekimab 改善了 3-5 期 CKD 伴系统炎症患者的贫血和铁稳态标志物,提示可能用于贫血管理。
研究设计与样本
- RESCUE 试验(NCT03926117)探索性终点分析,纳入 264 例 3-5 期 CKD 且 hs-CRP≥2 mg/L 的成人。
- 参与者按 1:1:1:1 随机接受安慰剂或 ziltivekimab 7.5、15、30 mg 皮下注射,每 4 周一次,最长 24 周。
- 本分析终点为基线至第 12 周血红蛋白和铁稳态生物标志物的变化。
- 试验因 COVID-19 大流行提前终止,故仅呈现第 12 周前数据。
主要发现
- 第 12 周时 ziltivekimab 7.5 mg 组血红蛋白较安慰剂组差异为 +0.57 g/dl(95%CI 0.27 至 0.86),P<0.001。
- 第 12 周时 ziltivekimab 15 mg 组血红蛋白较安慰剂组差异为 +1.05 g/dl(95%CI 0.76 至 1.33),P<0.001。
- 第 12 周时 ziltivekimab 30 mg 组血红蛋白较安慰剂组差异为 +0.99 g/dl(95%CI 0.70 至 1.28),P<0.001。
- ziltivekimab 所有剂量组第 12 周血清铁、总铁结合力和转铁蛋白饱和度较基线显著增加,与安慰剂比较 P<0.05。
- 持续血小板减少、持续中性粒细胞减少、贫血和缺铁性贫血事件少见且各组相似。
临床怎么用
- 对于 3-5 期 CKD 伴系统炎症(hs-CRP≥2 mg/L)的患者,ziltivekimab 可能作为改善贫血和铁稳态的潜在抗炎治疗选择。
- 仍需进一步临床试验验证 ziltivekimab 在 CKD 贫血管理中的作用。
局限性
- 本分析为探索性终点分析,试验因 COVID-19 大流行提前终止,仅呈现第 12 周前数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SIGNIFICANCE STATEMENT: Systemic inflammation in CKD can lead to anemia. Ziltivekimab, a fully human monoclonal antibody targeting the IL-6 ligand, has been shown to reduce systemic inflammation in patients with CKD. It has also been shown to increase serum albumin in patients on hemodialysis with inflammation and hyporesponsiveness to treatment with erythropoiesis-stimulating agents. This exploratory analysis of the RESCUE clinical trial found that among patients with CKD stage 3-5 and systemic inflammation, ziltivekimab treatment significantly increased hemoglobin (Hb) levels after 12 weeks compared with placebo. Ziltivekimab was also associated with significant increases in serum iron levels, total iron-binding capacity, and transferrin saturation. No major safety concerns were reported. Further clinical trials are warranted to study ziltivekimab's potential for anemia management in patients with CKD. BACKGROUND: In the phase 2 RESCUE clinical trial, ziltivekimab, a fully human monoclonal antibody against the IL-6 ligand, significantly reduced the biomarkers of inflammation compared with placebo, in patients with CKD and systemic inflammation (high-sensitivity C-reactive protein ≥2 mg/L). The aim of this subanalysis of RESCUE trial data was to assess the effect of ziltivekimab on Hb and iron homeostasis in this patient population. METHODS: This was an analysis of exploratory end points from the RESCUE trial ( NCT03926117 ), which included 264 adults with CKD stage 3-5 and high-sensitivity C-reactive protein ≥2 mg/L. Participants received placebo or subcutaneous ziltivekimab (7.5, 15, or 30 mg) (1:1:1:1) once every 4 weeks, up to 24 weeks. End points for this analysis were changes in Hb and biomarkers of iron homeostasis from baseline to week 12. RESULTS: The trial was terminated early due to the coronavirus disease 2019 pandemic, and thus, data up to week 12 are presented. Hb levels significantly increased from baseline to week 12 with ziltivekimab 7.5, 15, and 30 mg (treatment differences versus placebo: +0.57 g/dl [95% confidence interval, 0.27 to 0.86], +1.05 g/dl [0.76 to 1.33], and +0.99 g/dl [0.70 to 1.28], respectively, all P < 0.001). Ziltivekimab was associated with significant increases in serum iron levels, total iron-binding capacity, and transferrin saturation from baseline to week 12 ( P < 0.05 versus placebo for all doses and comparisons). Cases of sustained thrombocytopenia, sustained neutropenia, anemia, and iron deficiency anemia were infrequent and similar across all groups. CONCLUSIONS: Anti-inflammatory therapy with ziltivekimab improved the markers of anemia and iron homeostasis in people with stage 3-5 CKD and systemic inflammation, suggesting a possible role in anemia management.
引用
- Pergola PE, Davidson M, Jensen C, et al. Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3-5: An Analysis of a Randomized Trial (RESCUE). J Am Soc Nephrol. 2023. PMID: 38088558. doi:10.1681/ASN.0000000000000245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。